Modification by Cholecystokinin Octapeptide of the Binding of?-, ?-, and <sub>K</sub>-Opioid Receptors

Xiao-Jing Wang,Ji-Sheng Han
DOI: https://doi.org/10.1111/j.1471-4159.1990.tb03149.x
1990-01-01
Journal of Neurochemistry
Abstract:Previous study has shown that cholecystokinin (CCK) octapeptide (CCK‐8) suppressed the binding of opioid receptors to the universal opioid agonist [ 3 H]etorphine. In the present study, highly selective tritium‐labeled agonists for the μ‐ {[ tyrosyl ‐3,5‐ 3 H][d‐Ala 2 ,MePhe 4 ,Gly‐ol 5 ]enkephalin ([ 3 H]DAGO)}, δ‐ {[ tyrosyl ‐3,5‐ 3 H][d‐Pen 2,5 ]enkephalin ([ 3 H]DPDPE)}, and k ‐ ([ 3 H]U69,593) opioid receptors were used to clarify which type(s) of opioid receptor in rat brain homogenates is suppressed by CCK‐8. In the competition experiments, CCK‐8 suppressed the binding of [ 3 H]DAGO and [ 3 H]U69,593 but not that of [ 3 H]DPDPE to the respective opioid receptor. This effect was blocked by the CCK antagonist proglumide at 1 μmol/L. In the saturation experiments. CCK‐8 at concentrations of 0.1 nmol/L to 1 μmol/L decreased the B max of [ 3 H]DAGO binding sites without affecting the K D ; on the other hand, CCK‐8 increased the K D of [ 3 H]U69,593 binding without changing the B max . The results suggest that CCK‐8 inhibits the binding of μ‐ and K ‐opioid receptors via the activation of CCK receptors.
What problem does this paper attempt to address?